EXICURE Business Summary

Exicure, Inc. (XCUR) is an early-stage biotechnology company that has recently pivoted its business model from its proprietary Spherical Nucleic Acid (SNA) technology toward hematologic diseases and stem cell mobilization. The company generates revenue primarily through licensing and collaboration agreements, most notably with GPCR Therapeutics Inc., and potential future sublicensing income-sharing milestones. Its primary business segment is drug discovery, currently centered on the clinical development of Burixafor, a novel stem cell mobilizer that recently met primary endpoints in Phase 2 trials for multiple myeloma patients. Exicure operates as a micro-cap player within the highly volatile nucleic acid and immunotherapy sectors, facing direct competition from firms such as Genelux (GNLX), Oncolytics Biotech (ONCY), and Artiva Biotherapeutics (ARTV). Relative to these peers, Exicure is currently in a high-risk strategic restructuring phase, characterized by minimal current revenue and a focus on maximizing shareholder value through asset-light clinical milestones. Originally founded in 2011 by Dr. Chad Mirkin to commercialize SNA technology, Exicure is currently navigating a significant leadership vacuum following a wholesale executive overhaul in February 2026. As of February 17, 2026, the positions of Chief Executive Officer and Chief Financial Officer remain vacant following the simultaneous resignations of Andy Yoo (former CEO) and Seung Ik Baik (former CFO) on February 9, 2026. Governance is currently overseen by a reconstituted Board of Directors, which recently appointed Jung Kyu Ham, Jung Soo Kim, and Gyeung Seog Cheon to join remaining members Dongho Lee and Sangjin Yeo. Notable institutional backing has historically included Abbott Biotech Ventures, while Exicure HiTron Inc. remains a significant stakeholder despite recent open-market share liquidations. The current board is tasked with identifying new executive leadership to steer the company’s transition into its next clinical and strategic phase.